Longakit A, Urtatiz O, Luty A, Zhang C, Hess C, Yoo A
Cancer Res Commun. 2025; 5(2):209-225.
PMID: 39804140
PMC: 11788999.
DOI: 10.1158/2767-9764.CRC-24-0386.
Lucas C, Gross A, Romo C, Dehner C, Lazar A, Miettinen M
Neuro Oncol. 2024; 27(3):616-624.
PMID: 39500722
PMC: 11889724.
DOI: 10.1093/neuonc/noae235.
Cannizzaro I, Treccani M, Taiani A, Ambrosini E, Busciglio S, Cesarini S
Int J Mol Sci. 2024; 25(19).
PMID: 39409151
PMC: 11476461.
DOI: 10.3390/ijms251910822.
Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A
Clin Cancer Res. 2024; 30(23):5459-5472.
PMID: 39321200
PMC: 11866061.
DOI: 10.1158/1078-0432.CCR-24-1454.
Nguyen H, Kohl E, Bade J, Eng S, Tosevska A, Al Shihabi A
Cell Rep Methods. 2024; 4(5):100772.
PMID: 38744290
PMC: 11133839.
DOI: 10.1016/j.crmeth.2024.100772.
Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
Mitchell D, Burgess B, White E, Smith A, Sierra Potchanant E, Mang H
Clin Cancer Res. 2023; 30(5):1038-1053.
PMID: 38127282
PMC: 11095977.
DOI: 10.1158/1078-0432.CCR-23-2548.
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Wang J, Calizo A, Zhang L, Pino J, Lyu Y, Pollard K
Sci Adv. 2023; 9(47):eadg8876.
PMID: 38000020
PMC: 10672174.
DOI: 10.1126/sciadv.adg8876.
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
Sundby R, Rhodes S, Komlodi-Pasztor E, Sarnoff H, Grasso V, Upadhyaya M
Clin Trials. 2023; 21(1):40-50.
PMID: 37904489
PMC: 10922556.
DOI: 10.1177/17407745231203330.
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Lemberg K, Ali E, Krecmerova M, Aguilar J, Alt J, Peters D
Mol Cancer Ther. 2023; 22(12):1390-1403.
PMID: 37616542
PMC: 10690047.
DOI: 10.1158/1535-7163.MCT-23-0258.
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Larsson A, Bhatia H, Calizo A, Pollard K, Zhang X, Conniff E
Neuro Oncol. 2023; 25(11):2044-2057.
PMID: 37246765
PMC: 10628938.
DOI: 10.1093/neuonc/noad097.
MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding D, Amin N, He K, Zhang X, Lyu Y, Dehner C
Clin Cancer Res. 2023; 29(8):1592-1604.
PMID: 36799629
PMC: 10102849.
DOI: 10.1158/1078-0432.CCR-22-3722.
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.
Wang J, Calizo A, Zhang L, Pino J, Lyu Y, Pollard K
bioRxiv. 2023; .
PMID: 36778419
PMC: 9915673.
DOI: 10.1101/2023.02.02.526674.
Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka B, Sadek A, McKay R, Le L
Oncogene. 2022; 41(17):2405-2421.
PMID: 35393544
PMC: 9035132.
DOI: 10.1038/s41388-022-02290-1.
Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.
Bhalla A, Landers S, Singh A, Landry J, Yeagley M, Myerson G
Lab Invest. 2022; 102(6):658-666.
PMID: 35228656
DOI: 10.1038/s41374-022-00734-6.
RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas.
Imada E, Strianese D, Edward D, Althaqib R, Price A, Arnold A
Brain Pathol. 2021; 32(1):e13007.
PMID: 34297428
PMC: 8713532.
DOI: 10.1111/bpa.13007.
Chromosome 8 gain is associated with high-grade transformation in MPNST.
Dehner C, Moon C, Zhang X, Zhou Z, Miller C, Xu H
JCI Insight. 2021; 6(6).
PMID: 33591953
PMC: 8026192.
DOI: 10.1172/jci.insight.146351.
Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
Grit J, Johnson B, Dischinger P, Essenburg C, Adams M, Campbell S
Epigenetics Chromatin. 2021; 14(1):7.
PMID: 33436083
PMC: 7805211.
DOI: 10.1186/s13072-020-00380-6.
Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J, Pollard K, Calizo A, Pratilas C
Cancer Res. 2020; 81(3):747-762.
PMID: 33203698
PMC: 7854512.
DOI: 10.1158/0008-5472.CAN-20-1992.
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J, Pollard K, Allen A, Tomar T, Pijnenburg D, Yao Z
Cancer Res. 2020; 80(23):5367-5379.
PMID: 33032988
PMC: 7739379.
DOI: 10.1158/0008-5472.CAN-20-1365.
From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.
Lemberg K, Wang J, Pratilas C
Genes (Basel). 2020; 11(6).
PMID: 32599735
PMC: 7349243.
DOI: 10.3390/genes11060691.